Praxis Precision Medicines(NASDAQ) PRAX

Praxis Precision Medicines makes treatments for brain disorders. These medicines help stop seizures and involuntary shaking. The company focuses on patients with rare genetic conditions.

The Precision Medicine Toolkit

• Cerebrum Platform: Uses small molecules to create oral pills that adjust brain cell activity.
• Solidus Platform: Employs antisense oligonucleotides to target specific genetic causes of disease.
• Ulixacaltamide: Investigational drug for essential tremor, a condition causing involuntary shaking.
• Relutrigine: Oral treatment candidate for specific types of childhood epilepsy.
• Elsunersen: Targeted therapy for a rare genetic seizure disorder caused by specific gene variants.

Path to the Pharmacy

• Submitted a New Drug Application for ulixacaltamide to the FDA with a target action date of Jan. 29, 2027.
• Applied for FDA approval for relutrigine with an updated target action date of Dec. 27, 2026.
• Partnered with Remagine Labs in July 2026 to develop a wearable drug delivery patch.
• Completed a public offering in Jan. 2026 that generated approximately $621.2 million in net proceeds.
• Received breakthrough therapy designation from the FDA for elsunersen in June 2026.

A Virtual Approach to Discovery

Praxis utilizes a virtual research and development model, relying on external consultants, collaborators, and contract organizations to conduct its scientific activities. This strategy allows the firm to maintain a specialized internal team while accessing global expertise for drug manufacturing and clinical trials.

Checking the Balance Sheet

• Net loss was $176.3 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $1.4 billion as of June 30, 2026.
• Research and development expenses were $147.4 million for the six-month period ended June 30, 2026.
• Market cap reached $9.8 billion in Q2 2026, up 980.0% year over year.
• Accumulated deficit reached $1.3 billion as of June 30, 2026.

Ready for the Next Phase

Praxis has transitioned from early research toward potential commercial operations with multiple drugs awaiting regulatory decisions. Its dual-platform strategy targets both common movement disorders and rare genetic conditions.